Efficacy of Autologous Platelet-rich Plasma in the Treatment of Vitiligo: A 10-patient Prospective Study

Introduction: Vitiligo is an autoimmune disorder characterized by loss of epidermal melanocytes. It has cosmetic and psychosocial impact. The objective of this paper is to evaluate the interest of platelet-rich-plasma in the treatment of vitiligo.

Material And Methods: We conducted a prospective study between January 2019 and September 2021.

Results: Our descriptive study included 10 patients followed-up for vitiligo refractory to conventional therapies. The mean age was 36.2 years. Sex ratio was 0.25. Prior to platelet-rich-plasma treatment, vitiligo was stable in all cases. The mean number of platelet-rich-plasma sessions received by our patients was 2.6 (1-6). A visible improvement of lesions was obtained after a mean of 1.5 sessions. 40% of patients had obtained repigmentation of more than 50% for at least one lesion. An improvement of more than 75% (grade 4) was noted in 2 cases after a mean duration of 5.5 sessions. 40% of patients had obtained repigmentation of more than 50% for at least one lesion. A percentage of improvement between 50 and 74% (grade 3) was obtained for 2 patients. Four patients had an improvement of less than 25% (grade 1) after a mean of 1.75 sessions. There was no recurrence of depigmentation after a mean follow-up of 6 months (1 to 24 months).

Conclusion: Our series proves the benefit of platelet-rich-plasma in the treatment of vitiligo. It is a safe and promising option for stable lesions in different body sites with few side effects.